EMA Authorised: Qinlock (ripretinib) — Deciphera Pharmaceuticals (Netherlands) B.V.

View source ↗

Summary

The EMA has authorised Qinlock (ripretinib) for use in adults with gastrointestinal stromal tumors, and the medicine carries orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• QINLOCK (ripretinib)

Snippet

Status: Authorised. Therapeutic area: Gastrointestinal Stromal Tumors. MAH: Deciphera Pharmaceuticals (Netherlands) B.V.. Decision date: 11/02/2026. Orphan medicine